The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

GW Pharmaceuticals PLC

Nasdaq: GWPH
Last

(U.S.) $111.25

Today's change+0.11 +0.10%
Updated October 16 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

GW Pharmaceuticals PLC

Nasdaq: GWPH
Last

(U.S.) $111.25

Today's change+0.11 +0.10%
Updated October 16 4:00 PM -4GMT. Delayed by at least 15 minutes.

GW Pharmaceuticals PLC up slightly

GW Pharmaceuticals PLC closed up just (U.S.)$0.11 Monday to (U.S.)$111.25. Over the last five days, shares have gained 1.48%, but are currently unchanged over the last year to date. Shares have underperformed the S&P 500 by 31.89% during the last year.

Key company metrics

  • Open(U.S.) $111.88
  • Previous close(U.S.) $111.14
  • High(U.S.) $113.38
  • Low(U.S.) $110.64
  • Bid / Ask(U.S.) $111.26 / (U.S.) $113.00
  • YTD % change-0.45%
  • Volume158,283
  • Average volume (10-day)422,441
  • Average volume (1-month)383,208
  • Average volume (3-month)328,271
  • 52-week range(U.S.) $92.65 to (U.S.) $136.95
  • Beta2.68
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$5.66
Updated October 16 4:00 PM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-1,380.93%

Although this company's net profit margin is negative, it is above the industry average and implies that GW Pharmaceuticals PLC is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.03%Sector:Industry:

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2017Q2/2017Q1/2017Q4/2016
Fiscal Quarter Endvalues in $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue2222
Total other revenue--------
Total revenue2222
Gross profit1111
Total cost of revenue1111
Total operating expense49412026
Selling / general / administrative12977
Research & development28272524
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-47-39-18-25
Interest income (expense), net non-operating0000
Gain (loss) on sale of assets--------
Other--------
Income before tax-47-39-18-24
Income after tax-40-34-16-17
Income tax, total-6-5-3-8
Net income-40-34-16-17
Total adjustments to net income--------
Net income before extra. items-40-34-16-17
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-40-34-16-17
Inc. avail. to common incl. extra. items-40-34-16-17
Diluted net income-40-34-16-17
Dilution adjustment--0----
Diluted weighted average shares304304303295
Diluted EPS excluding extraordinary itemsvalue per share-0.13-0.11-0.05-0.06
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.13-0.11-0.05-0.06